These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease. Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994 [TBL] [Abstract][Full Text] [Related]
7. [Etiology of Basedow's disease, with special reference to LATS]. Nagata K Naika Hokan; 1969 Jul; 16(7):297-317. PubMed ID: 4901097 [No Abstract] [Full Text] [Related]
8. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator. Pequegnat EP; Mayberry WE; McConahey WM; Wyse EP Mayo Clin Proc; 1967 Dec; 42(12):802-11. PubMed ID: 4169552 [No Abstract] [Full Text] [Related]
9. [Simultaneous study of LATS and antimicrosomial antibodies in untreated Basedow's disease]. Orgiazzi J; Pousset G; Durand H Presse Med (1893); 1971 May; 79(25):1167-8. PubMed ID: 4933634 [No Abstract] [Full Text] [Related]
10. [Characterization of the long-acting thyroid stimulator. Considerations on preliminary results]. Tourneur R; Letonturier P; Sénécal P MMW Munch Med Wochenschr; 1974 Mar; 116(13):677-9. PubMed ID: 4212576 [No Abstract] [Full Text] [Related]
11. Complex investigation of Graves'-Basedow disease: case report. Luca IC; Bene MC; Cotuţiu C Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):202-4. PubMed ID: 10756799 [TBL] [Abstract][Full Text] [Related]
12. Mitotic index in toxic diffuse goitres. Nilsson G Ann Clin Res; 1974 Jun; 6(3):142-5. PubMed ID: 4407913 [No Abstract] [Full Text] [Related]
13. [Combination of low doses of 131-iodine and synthetic antithyroid agents for prolonged treatment in Basedow's disease. Apropos of 165 cases]. Mitouze J; Jaffiol C; Baldet L; Ghachem M Rev Fr Endocrinol Clin; 1972; 13(4):339-61. PubMed ID: 4122472 [No Abstract] [Full Text] [Related]
14. [Simultaneous determination of thyreotropic hormone and long-acting thyroid stimulator in the plasma of Basedow patients]. Földes J; Gesztesi E; Takács I Orv Hetil; 1970 Dec; 111(52):3067-70. PubMed ID: 4099957 [No Abstract] [Full Text] [Related]
15. [Study of the relationship between Basedow's disease and Hashimoto thyroiditis]. Földes J; Takó J; Bános C; Gesztesi E; Juhász J Orv Hetil; 1971 Apr; 112(17):968-71. PubMed ID: 5108752 [No Abstract] [Full Text] [Related]
16. [A differential diagnosis: toxic adenoma or partial thyroid agenesis with Basedow's disease of the remaining lobe]. Mirouze J; Jaffiol C; Seignalet J; Pastorello R; Baldet L Rev Fr Endocrinol Clin; 1967; 8(2):161-4. PubMed ID: 6072294 [No Abstract] [Full Text] [Related]
17. Long-acting thyroid stimulator (LATS) in toxic nodular goitre, toxic adenoma and Graves' disease. Lamberg BA; Gordin A; Viherkoski M; Kvist G Acta Endocrinol (Copenh); 1969 Oct; 62(2):199-209. PubMed ID: 5394703 [No Abstract] [Full Text] [Related]
18. Hyperthyroidism. Wool MS Major Probl Clin Surg; 1980; 15():102-19. PubMed ID: 7003266 [No Abstract] [Full Text] [Related]
19. [Abnormality and deficiency in cellular immunity and internal diseases--Basedow's disease and cellular immunity]. Shishiba Y Nihon Rinsho; 1978; 36(5):960-6. PubMed ID: 353330 [No Abstract] [Full Text] [Related]
20. [Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options]. Campos Pastor MM; Fernández Soto ML; Escobar-Jiménez F; Barredo Acedo F; Ruiz de Almodóvar M Med Clin (Barc); 1994 Apr; 102(12):446-50. PubMed ID: 7516033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]